Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06107725 · ClinicalTrials.gov registry record · Phase 2
Maimonides Minocycline in Stroke Study
A Phase 2 study, sponsored by Maimonides Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT06107725 is a Phase 2 study that was terminated before completion, run by Maimonides Medical Center. The registered enrollment target is 2 participants.
The verdict
NCT06107725, a Phase 2 study, was terminated before completion, sponsored by Maimonides Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The goal of this study is to determine if oral Minocycline's proposed neuroprotective effects further improve the clinical outcomes, including mortality, of acute stroke patients beyond the current standard stroke care in a large scale randomized prospective open label (outcome assessor blinded) clinical trial. Participants will be randomly assigned (1:1) to take Minocycline 200mg orally every 24 hours for five days, starting within 24 hours from stroke symptoms onset, in addition to standard care or standard care alone. NIHSS (The National Institutes of Health Stroke Scale) and mRS (Modified Rankin Scale) will be collected at the time of presentation, discharge and again at 30- and 90-days post-discharge. All-cause mortality will also be obtained at 30 days and 90 days.
Interventions
- DRUG Minocycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2024-05-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06107725
The ClinicalTrials.gov registry entry for NCT06107725 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Maimonides Medical Center, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Minocycline is the first listed.
NCT06107725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06107725 about?
NCT06107725 is a clinical study titled "Maimonides Minocycline in Stroke Study". The goal of this study is to determine if oral Minocycline's proposed neuroprotective effects further improve the clinical outcomes, including mortality, of acute stroke patients beyond the current standard stroke care in a large scale randomized prospective open label (outcome assessor blinded) cli...
What is the current status of trial NCT06107725?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2023-11-01. Estimated completion is 2024-05-09.
What interventions are being tested in trial NCT06107725?
The interventions under investigation include: Minocycline (DRUG).
Who is sponsoring clinical trial NCT06107725?
This trial is sponsored by Maimonides Medical Center, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.